Cogent Biosciences announced updated preclinical data from the Company’s pipeline programs, including its novel EGFR-sparing brain-penetrant ErbB2 inhibitor and its next-generation selective fibroblast growth factor receptor 2 program. The data are being presented in poster sessions at the American Association for Cancer Research, AACR, 2023 Annual Meeting. Cogent also announced the initiation of Part 2 of the Company’s ongoing APEX trial with bezuclastinib in Advanced Systemic Mastocytosis. "We are pleased to share our progress highlighting the Cogent Research Team in their ongoing effort to discover and advance potential best-in-class novel therapies for rare disease populations with high unmet medical need," said Andrew Robbins, Cogent’s President and Chief Executive Officer. "Separately, based on bezuclastinib’s impressive and consistent clinical activity, safety and tolerability, we are also excited to announce the initiation of Part 2 of the APEX trial in AdvSM at a once-daily dose of 150 mg. We remain on track to provide clinical updates in the second half of 2023 from both APEX and SUMMIT, our trial of bezuclastinib in NonAdvSM patients, as well as updated clinical results from the PEAK lead-in trial in GIST patients this quarter."
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on COGT:
- Cogent Biosciences Presents Preclinical Data at AACR Annual Meeting Highlighting Precision Therapy Pipeline and Announces Initiation of Part 2 of the Registration-Enabling APEX Trial with Bezuclastinib in Advanced Systemic Mastocytosis
- Cogent Biosciences Announces Participation at Upcoming Investor Conferences
- Cogent Biosciences assumed with a Buy at H.C. Wainwright
- Cogent Biosciences treatment of mastocytosis granted orphan status
- Cogent Biosciences price target lowered to $23 from $24 at Needham